For the overall study population, our study did not detect a significant association between the GSTP1 Ile105Val polymorphism and gynecological cancer risk in any of the genetic models (GG vs. AA: OR = 1.41, 95% CI = 0.75-2.26; AG vs. AA: OR = 1.13, 95% CI = 0.74-1.73; AG/GG vs. AA: OR = 1.17, 95% CI = 0.75-1.81 (Figure 2); GG vs. AA/AG: OR =1.38, 95% CI = 0.79-2.42). This evidence concerns the gene GSTP1 and female reproductive organ cancer.